• K-Pop Herald
  • The Investor
  • The Herald Business
  • The Herald POP
  • Real Foods
  • Inspire
  • NEWSLETTER
  • SIGN IN
  • MOBILE
  • Home
  • National
  • Business
  • Finance
  • Life&Style
  • Entertainment
  • Sports
  • World
  • Opinion
  • Weekender
  • English Eye
  • Subscribe
  • National Politics Social Affairs Foreign Affairs Defense North Korea Science Diplomatic Circuit Education
  • Business Industry Technology Transport Retail
  • Finance Economy Market Money
  • Life&Style Culture Travel Fashion Food & Beverage Books People Expat Living Arts & Design Health
  • Entertainment Film Television Music Theater K-pop
  • Sports Soccer Baseball Golf More Sports
  • World World News World Business
  • Opinion Editorial Viewpoints
  • English Eye Podcast English Cafe
  • Korean
  • Mobile App
  • PDF
  • Twitter
  • Facebook
  • Youtube
  • RSS
Go to Mobile Version

Articles by Lim Jeong-yeo

LATEST NEWS
  • [Elizabeth Drew] Why would anyone want to be president?
  • [Peter Singer] Extending the right to die
  • [Editorial] Self-inflicted disgrace
  • Official: Chinese vaccines' effectiveness low
  • Thailand hits new daily record with nearly 1,000 virus cases
  • Mideast 'early inoculators' to recover by 2022: IMF
  • SK Innovation reaches W2tr settlement in battery row with LG Energy Solutio...
  • Cheong Wa Dae denies report US requested S. Korea join Quad
  • Samsung invited to White House meeting on chip shortage
  • N. Korea may be modifying submersible missile test barge: 38 North
  • March 1, 2021   Industry

    [Herald Interview] Carbon-neutral Philips sets higher goals for 2025

    For anyone who has tried, it is evident that reducing one’s carbon footprint requires an extraordinary attention to the waste produced, coupled with a conscious effort to cut down on convenient habit...

  • GC WellBeing to repurpose liver drug as COVID-19 treatment

    GC WellBeing will conduct a phase 2 clinical trial of its liver drug Laennec, to repurpose it as a COVID-19 treatment, the Ministry of Food and Drug Safety said Friday. This puts the total count of ...

    February 26, 2021

    Industry
  • Pfizer vaccine approval in Korea imminent, FDA allows more flexible storage

    South Korea on Friday paved the way to approving Pfizer’s mRNA vaccine for COVID-19 as another group of pharmaceutical experts positively opined on the vaccine’s efficacy and safety. On the same day...

    February 26, 2021

    Industry
  • EMA starts rolling review of Celltrion’s COVID-19 treatment

    European Medicines Agency said Wednesday, local time, that it has started a “rolling review” of data on South Korean company Celltrion’s monoclonal antibody regdanvimab. Regdanvimab, also known as C...

    February 25, 2021

    Industry
  • Christopher Ko shares visions as Bio association representative

    South Korean biosimilar maker Samsung Bioepis’ CEO Christopher Ko on Wednesday carried out his first public event as the new chairperson of the Korea Bio Association. Korea Bio is an association rep...

    February 24, 2021

    Industry
  • Elekta’s next-gen MRI device offers new hope for cancer patients

    Swedish medical device company Elekta wants to give renewed hopes to cancer patients through its next-generation radiotherapy device Unity. Elekta on Wednesday launched Unity in Korea, making it the...

    February 24, 2021

    Industry
  • Korean experts advise Pfizer vaccine for 16 and older

    The first of the three-part evaluation of Pfizer’s COVID-19 vaccine here has shown the vaccine to be 95 percent effective and eligible for use on those aged 16 and older, South Korea’s Drug Ministry ...

    February 23, 2021

    Industry
  • [Herald Interview] Software dons role of therapeutics

    When talking about medical devices, conventional hardware with analytical or therapeutic functions for human health usually come to mind. But computer software that seeks to cure or alleviate sympto...

    February 22, 2021

    Industry
  • Macrogen, Lifex Biolabs to research Parkinson’s treatment

    Precision life science company Macrogen will collaborate with US-based Lifex Biolabs on Parkinson’s disease treatment research, Macrogen announced Monday. This is a follow-up to Macrogen’s strategic...

    February 22, 2021

    Industry
  • Samsung Display joins responsible business alliance

    Samsung Display’s chief executive officer Choi Joo-sun is aiming to further embolden the company’s environmental, social and governance (ESG) involvement beginning this year. As part of this drive, ...

    February 21, 2021

    Industry
  • Celltrion to take on S. Africa variant

    Only a day after Celltrion began distribution of its monoclonal antibody therapy for COVID-19 in Korea, the company announced Thursday that it is setting out to tackle the more contagious South Afric...

    February 18, 2021

    Industry
  • Celltrion begins distribution of COVID-19 therapy in Korea

    Celltrion began nationwide distribution of its monoclonal antibody therapy for COVID-19 on Wednesday. Celltrion’s regdanvimab is Korea’s first emergency-approved COVID-19 treatment. All 156 state-d...

    February 17, 2021

    Industry
  • [News Focus] More homegrown COVID-19 therapies coming

    Following Celltrion’s monoclonal antibody treatment for COVID-19, a slew of homegrown therapies is on the way in the first half of 2021. Chong Kun Dang Pharmaceutical is set to submit application fo...

    February 16, 2021

    Industry
  • SK Bioscience to manufacture Novavax vaccine for 20 mil population

    South Korean vaccine-maker SK Bioscience will manufacture 40 million doses of US’ Novavax vaccines, enough to inoculate 20 million people. Under the agreement signed by SK Bioscience, Korea Disease ...

    February 16, 2021

    Industry
  • Celltrion’s Humira biosimilar gains European sales approval

    Celltrion’s Yuflyma, an adalimumab biosimilar for autoimmune diseases, has been given the green light by the European Commission on Feb. 11, allowing for it to be sold in the European market, Celltri...

    February 15, 2021

    Industry
  • prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • next
  • ANNOUNCEMENT
  • CS CENTER
  • CONTACT US
  • LOCATION
  • ABOUT KOREA HERALD
  • ABOUT HERALD CORPORATION
  • twitter
  • facebook
  • youtube

The Korea Herald by Herald Corporation

Copyright Herald Corporation. All Rights Reserved.

  • PRIVACY STATEMENT
  • COPYRIGHT POLICY
  • HERALD OMBUDSMAN

Address : Huam-ro 4-gil 10, Yongsan-gu,Seoul, Korea
Online newspaper registration No : Seoul 아03711
Date of registration : 2015.04.28
Publisher. Editor : Kwon Chung-won
Juvenile Protection Manager : Yang Sung-jin
Tel : 02.727.0114